'Urinary tract infection left me housebound'

Women with chronic urinary tract infections say the pain can last for years and make it impossible to live a normal life.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news

Related Links:

SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Cochrane Database Syst Rev. 2021 Nov 16;11:CD013647. doi: 10.1002/14651858.CD013647.pub2.ABSTRACTBACKGROUND: Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, with an unpredictable course. Current MS therapies such as disease-modifying therapies focus on treating exacerbations, preventing new exacerbations and avoiding the progression of disability. Siponimod (BAF312) is an oral treatment, a selective sphingosine-1-phosphate (S1P) receptor modulator, for the treatment of adults with relapsing forms of MS including active, secondary progressive MS with relapses.OBJECTIVES: To assess...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research
Blood Adv. 2021 Nov 1:bloodadvances.2021005621. doi: 10.1182/bloodadvances.2021005621. Online ahead of print.ABSTRACTZanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were pooled from 6 studies (N=779). Assessments included type, incidence, severity, and outcome of TEAEs. Median age was 65 years; 20% were ≥75 years old. Most patients had Waldenström macroglobulinemia (33%), chr...
Source: Adv Data - Category: Epidemiology Authors: Source Type: research
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conditions:   Urologic Diseases;   Patient Satisfaction;   Pain, Chronic;   Sexual Dysfunction Intervention:   Other: Non-interventional Cross-sectional Patient Reported Outcome Measure Development Sponsors:   University of Reading;   Live UTI Free;   University of Buckingham Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionThese results indicate that after TIPP it is feasible and safe to perform re-surgery for recurrent inguinal hernia with an anterior approach again. For these recurrences, a Lichtenstein repair can be performed, or a"re-TIPP if possible"  strategy can be applied by experienced TIPP surgeons, tailored to the intraoperative findings. Whether a re-TIPP has advantages over Lichtenstein should be evaluated in a prospective manner.
Source: Hernia - Category: Sports Medicine Source Type: research
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson &Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque ps...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Discussion Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory disease with a strong autoimmune association. It can occur with other autoimmune diseases. Its specific cause is unknown. It affects females and males of all ages, but especially females 40-60 years. In the pediatric population it affects prepubertal females most often. Treatment includes steroid medications or anti-inflammatory medications. Other treatments may be offered including phototherapy, and much less commonly systemic steroids or immunosuppressive therapy. Circumcision may also be an option for some males. Childhood LSA generally improves b...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
We present a series of 32 patients who received intravesical instillations of hyaluronic acid. Demographic characteristics, tolerance, and complications were analyzed, and symptoms before and after treatment were compared. Symptomatic relief achieved with treatment was assessed using the Patient Global Improvement Impression Scale (PGI-I).RESULTS: The median age was 74 years (IQR 60-78) and 65.6% were women. Median follow-up was 10 months (IQR 7-14). Eleven patients were diagnosed with radiotherapy-induced cystitis, 17 with bladder pain syndrome/interstitial cystitis (BPS/IC), and 4 with recurrent cystitis. After treatment...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Authors: Source Type: research
More News: Chronic Pain | Health | Pain | Urinary Tract Infections | Women